Benjamin Hohl, CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 6,250 shares at $28.49 ($178K) on 2024-10-28, disclosed to the SEC on 2024-10-30.
Scheduled sale ($178k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $28.49 | 5,600 | $160K | 89.4% |
| 2 | $29.11 | 650 | $19K | 10.6% |
| Total | $28.55 avg | 6,250 | $178K | 100% |
| Filing → |
| ELVN | SELL | 2026-07-21 | $317K | — | Filing → |
| ELVN | SELL | 2026-06-22 | $264K | — | Filing → |
| ELVN | SELL | 2026-03-10 | $296K | — | Filing → |